Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study. Hua LH, Brown B, Camacho E, Chinea AR, et al. J Neurol 2025;272:725.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hua LH, Brown B, Camacho E, Chinea AR, et al. Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study. J Neurol 2025;272:725.
PMID: 41196386